cross-sectional incidence testing; HIV; HSV-2; viral diversity; HIV pathogenesis; developing countries; resource-limited settings
Experiences & Accomplishments
Johns Hopkins Bloomberg School of Public Health
Johns Hopkins Carey Business School
Johns Hopkins University
Dr. Laeyendecker is a scientist and administrator. He manages Dr. Thomas Quinn’s International HIV Laboratory. He has worked at Johns Hopkins University on infectious diseases projects for more than 20 years. The strategic mission of the International HIV Laboratory is to investigate: (1) develop methods for epidemiologic investigation of HIV, HCV and HSV-2 with an emphasis on being able to estimate incidence from cross-sectional surveys; (2) examine epidemiologic, clinical, virologic, and immunologic features of HIV infection in the United States and in developing countries; (3) examines the viral kinetics and other biological and behavioral factors associated with HIV transmission; (4) characterizes the molecular strains of HIV by region for differences in pathogenesis, infectiousness, transmission, and immunologic response; (5) develops and evaluates novel interventions to prevent HIV transmission, including microbicides, circumcision and vaccines; (6) examines the efficacy of antiretroviral drugs in preventing transmission and increasing survival in developing countries. In addition to research projects Dr. Laeyendecker is involved in the development and support of laboratory projects in Uganda. These include the Intramural Center for Excellence in Research (ICER) laboratory facility in Kalisizo, Uganda, at the Rakai Health Sciences Project, and the Infectious Diseases Institute in Kampala Uganda.
Honors & Awards
Special Act Award, Division of Intramural Research, NIH/NIAID 2009 Performance Award, Division of Intramural Research, NIH/NIAID 2011, 2010, 2008, 2007, 2006, 2005 Quality Step Increase Award, Division of Intramural Research, NIH/NIAID 2003 Staff Recognition Award, Division of Intramural Research, NIH/NIAID 2002, 2001, 2004
Publications that cover the research topics I am involved in.
- Ng OT, Eyzaguirre LM, Carr JK, Chew KK, Lin L, Chua A, Leo YS, Redd AD, Quinn TC, Laeyendecker O. Identification of New CRF51_01B in Singapore using full genome analysis of three HIV type 1 isolates. 2012; 28:527-30. PMC3585921.
- Laeyendecker O, Brookmeyer R, Cousins MM, Mullis CE, Konikoff J, Donnell D, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Mehta SH, Astemborski J, Jacobson LP, Margolick JB, Brown J, Quinn TC, Eshleman SH. HIV incidence determination in the United States: a multiassay approach. J Infect Dis. 2013; 207:232-9. PMC353826.
- Longosz AF, Mehta SH, Gregory D. Kirk GD, Margolick JB, Brown J, Quinn TC, Eshleman SH, and Laeyendecker O. Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay. AIDS, 2014; 28:1227-1232. PMC4102639.
- Laeyendecker O, Redd AD, Nason M, Longosz AF, Karim QA, Naranbhai V, Garrett N, Eshleman SH, Karim SS, Quinn TC. Antibody Maturation in Women who Acquire HIV Infection While Using Antiretroviral Pre-Exposure Prophylaxis. J Infect Dis. 2015; 212:754-9. PMC4539904.
- Patel EU, Cox AL, Mehta SH, Boon D, Mullis CE, Astemborski J, Osburn WO, Quinn J, Redd AD, Kirk GD, Thomas DL, Quinn TC, and Laeyendecker O. Hepatitis C IgG antibody avidity as a biomarker to estimate population-level incidence. 2016 Epub ahead of print J Infect Dis.
ARV effects on HIV epidemiology & behaviors, Rakai Uganda (through the Rakai Health Sciences Program)
The effect of HIV subtype and coreceptor tropism on transmission and progression of diseases
Algorithms for improved cross sectional incidence testing for HIV
Molecular Epidemiology of HIV